The expanded programme addresses longstanding inequalities in technology adoption across different NHS regions. Technologies meeting NICE's standards will receive strong recommendations for NHS-wide ...

NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this ...

NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.

Adults diagnosed with a functional neurological disorder are supported to manage symptoms that are a part of the disorder in non-specialist care. Adults with symptoms that occur as part of a ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review NG251 5 September 2025 5 September 2025 ...

This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing ...

NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because ...

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...